logo
Share SHARE
FONT-SIZE Plus   Neg

ChemoCentryx Completes IPO

ChemoCentryx, Inc. (CCXI) said Monday that it has completed its initial public offering of 4.5 million shares of common stock.

In addition, the underwriters of the initial public offering exercised their over-allotment option in full and purchased an additional 675,000 shares of common stock.

All of such shares were sold by ChemoCentryx at an initial public offering price of $10.00 per share.

J.P. Morgan and Citigroup acted as joint book-running managers of the offering, and Cowen and Company acted as co-manager of the offering.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The recent week marked the lull before the storm, with very few market moving economic numbers released during the week. However, the economic news flow picks up pace in the upcoming week, offering glimpses into every vehicle of economic growth, ranging from consumers to private sector activity to housing.... Life expectancy at birth in the U.S. is already lower than most other developed nations and is now projected to fall further behind by 2030, according to a new study. It also suggests that by 2030, national female life expectancy in South Korea could break the 90 year barrier. Department store chain J.C. Penney Co. Inc. on Friday reported a turnaround to profit in the fourth quarter as a slight decline in sales was more than offset by lower expenses. Adjusted earnings per share for the quarter beat analysts' expectations, while revenues slightly missed their estimates. Earlier today, J.C. Penny announced a plan to optimize its national retail operations.
comments powered by Disqus
Follow RTT